Breaking News, Collaborations & Alliances

Recipharm, RedHill Biopharma Ink Commercial Mfg. Pact

CDMO to provide commercial manufacturing to support Talicia launch following FDA approval.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Recipharm, the contract development and manufacturing organization (CDMO), has entered an ongoing large-scale commercial manufacturing agreement with RedHill Biopharma for its drug, Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg/250 mg/12.5 mg. Market launch is planned for the first quarter 2020.    RedHill and Recipharm have been working in partnership since 2015 to develop and manufacture the product, which is the first rifabutin-based therapy approv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters